| Dr Zahida Bhatti, MD | |
|
1202 State Street, Erie, PA 16501-1914 | |
| (814) 454-4530 | |
| (814) 456-2375 |
| Full Name | Dr Zahida Bhatti |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 32 Years |
| Location | 1202 State Street, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932208584 | NPI | - | NPPES |
| 1017796880001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MD429956 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Hamot Hospital | Erie, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Health Services Inc | 4880593722 | 484 |
News Archive
Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
› Verified 8 days ago
| Entity Name | Regional Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174520654 PECOS PAC ID: 4880593722 Enrollment ID: O20040108000694 |
News Archive
Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
› Verified 8 days ago
| Entity Name | Clarion University Of Pennsylvania |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225241805 PECOS PAC ID: 7719924703 Enrollment ID: O20100104000099 |
News Archive
Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
› Verified 8 days ago
| Entity Name | Multi-cultural Health Evaluation Delivery Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730227307 PECOS PAC ID: 9537299730 Enrollment ID: O20100615000504 |
News Archive
Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zahida Bhatti, MD 100 Shenango Ave, Sharon, PA 16146-1503 Ph: (814) 455-5505 | Dr Zahida Bhatti, MD 1202 State Street, Erie, PA 16501-1914 Ph: (814) 454-4530 |
News Archive
Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
› Verified 8 days ago
Bushra Rizvi, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 300 State St Ste 103a, Suite 103a, Erie, PA 16507 Phone: 814-877-8540 | |
Debjit Saha, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-4922 Fax: 814-877-3622 | |
Mr. Pradeep Dayanand, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 2315 Myrtle St Ste 190, Erie, PA 16502 Phone: 814-453-7767 Fax: 814-454-6667 | |
Dr. James Pawlak Iii, DO Infectious Disease Medicare: Medicare Enrolled Practice Location: 5515 Peach St, Erie, PA 16509 Phone: 814-864-4031 | |
Dr. Theresa J Fryer, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 3317 Liberty St, Erie, PA 16508 Phone: 814-868-8531 Fax: 814-866-1439 | |
Mohamad Khaled Sabeh, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2315 Myrtle St Ste 190, Erie, PA 16502 Phone: 814-453-7767 Fax: 814-454-6667 | |
Dr. Edward C Clark, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 311 W 24th St, Suite 402, Erie, PA 16502 Phone: 814-453-6687 Fax: 814-456-4676 |